MESA, AZ / ACCESS Newswire / April 23, 2026 / Medical Care Technologies Inc. (OTC PINK:MDCE) today announced a strategic...
HOUSTON, April 23, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a healthcare company developing...
Completed enrolment in Phase 2b clinical trial of imaging agent RAD 101 in patients with recurrent brain metastases following earlier...
TNX-1700 (TFF2-albumin fusion protein) reversed aging-associated gastric inflammation and significantly attenuated tumor progression in aged gastric microenvironment in preclinical models...
Moderna to host an investor event via webcast on Monday, June 1 at 6:15 PM CDT CAMBRIDGE, MA / ACCESS...
Moderna to host an investor event via webcast on Monday, June 1 at 6:15 PM CDT CAMBRIDGE, MA / ACCESS...
Moderna to host an investor event via webcast on Monday, June 1 at 6:15 PM CDT CAMBRIDGE, MA / ACCESS...
Bria-OTS+ platform provides early, potent and durable activation of innate and adaptive immunity in in-vitro cancer cell line modelsImmune cells...
Confirmed responses deepened with an average maximum tumor reduction from baseline of 89% and median time on treatment increased to...
The U.S. FDA has granted Fast Track designation for mRNA-4359 in combination with pembrolizumab for the treatment of checkpoint inhibitor...
Targets rare, high-burden genetic condition with no approved therapies; advances non-surgical treatment strategy for recurrent basal cell carcinomaPHILADELPHIA, April 17,...
Company leverages proven AI deployment capabilities to accelerate clinical-grade healthcare solutions. MESA, AZ / ACCESS Newswire / April 16, 2026...
AGOURA HILLS, Calif., April 16, 2026 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB:OTLC) (“Oncotelic”, the “Company” or “We”), a clinical-stage...
PITTSBURGH, PA / ACCESS Newswire / April 14, 2026 / The World Tumor Registry ("WTR"), a global non-profit organization with...
Phio invites investors, advisors and analysts with an interest in the life sciences sector to attend this virtual eventR. Todd...
WOBURN, Mass., April 10, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the...
Preclinical models demonstrate potential to restore thymic function lost with aging reducing susceptibility to cancer, autoimmune diseases, infections, and reduced...
WEST CHESTER, Pa., April 09, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a therapeutics company developing and...
Investors and Advisors, and Life Sciences Analysts are Invited to Attend the New York City Event; Virtual Webcast Link Available...
Trial extension completed as planned with three-year clinical efficacy data expected to be presented in the second half of 2026The...